Literature DB >> 3968505

Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats.

R G Clark, J O Jansson, O Isaksson, I C Robinson.   

Abstract

Young hypophysectomized rats were maintained with chronic indwelling i.v. cannulae attached via swivels to a multichannel pumping system programmed to deliver GH in a continuous or pulsatile pattern for several days. Continuous i.v. infusions of human GH for 5 days produced dose-dependent increases in body weight and tail length, without increasing food intake. A comparison of GH infusions by the s.c. or i.v. route showed that the direct i.v. route was threefold more effective. Pulsatile i.v. infusions of human or bovine GH at two doses (12 or 36 mu./day, eight pulses/day, 5-min duration, every 3 h) produced greater increases in body weight than continuous i.v. infusions of GH at the same daily dose. Continuous infusions of bovine GH produced a lower growth rate in the second of two consecutive 5-day treatment periods, whereas the responses to pulsatile GH did not diminish with time. Both body weight gain and long-bone growth were affected by the frequency of GH pulses; nine pulses per day were more effective than three pulses per day which in turn produced larger growth responses than one pulse per day. Keeping GH pulse frequency constant and varying pulse duration (4, 16 or 64 min) did not affect growth rates. In conclusion, long-term pulsatile i.v. infusions of GH mimic the endogenous secretory pattern, and are most effective when given at the physiologically appropriate pulse frequency.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3968505     DOI: 10.1677/joe.0.1040053

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  25 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Optimization of growth hormone therapy in growth hormone deficient children.

Authors:  S M De Muinck Keizer-Schrama
Journal:  Indian J Pediatr       Date:  1991 Sep-Oct       Impact factor: 1.967

3.  Long-acting growth hormone.

Authors:  Charlotte Höybye; Jens Sandahl Christiansen
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

Review 4.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

Review 5.  The relevance of pharmacokinetics in the development of biotechnology products.

Authors:  S Toon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

6.  Dynamic testosterone responses to near-physiological LH pulses are determined by the time pattern of prior intravenous LH infusion.

Authors:  Johannes D Veldhuis; Peter Y Liu; Paul Y Takahashi; Daniel M Keenan
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-17       Impact factor: 4.310

7.  The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency.

Authors:  Y J Janssen; M Frölich; F Roelfsema
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

8.  Growth hormone enhances hepatic epidermal growth factor receptor concentration in mice.

Authors:  J O Jansson; S Ekberg; S B Hoath; W G Beamer; L A Frohman
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

9.  The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models.

Authors:  P A Baldwin; C K Klingbeil; C J Grimm; J P Longenecker
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

10.  Intermittent versus continuous administration of growth hormone treatment.

Authors:  V Hakeem; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.